Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 2/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSE | P14091 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893802 | 0.87 | — | — | |
| SCHEMBL8896931 | 0.87 | — | — | |
| SCHEMBL8893313 | 0.87 | — | — | |
| SCHEMBL8896166 | 0.87 | — | — | |
| SCHEMBL8895976 | 0.85 | — | — | |
| SCHEMBL8893116 | 0.80 | MEN1 (0.36) | LTA4HHPGDALDH1A1KMT2A | |
| SCHEMBL8893427 | 0.78 | MEN1 (0.37) | LTA4HHPGDALDH1A1KMT2A | |
| SCHEMBL8895729 | 0.77 | L3MBTL1 (0.34) | LTA4HHPGDALDH1A1KMT2A | |
| SCHEMBL8893928 | 0.77 | ABCB1 (0.40) | LTA4HALDH1A1KMT2A | |
| SCHEMBL8897443 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645738-B2 | 18-membered nitrobenzyl- and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites and a process for their preparation | BAYER ANIMAL HEALTH GMBH (DE) | 2010-01-12 | — | — | US | disclosed |
| US-20080026990-A1 | 18-Membered Nitrobenzyl- and Aminobenzyl-Substituted Cyclohexadepsipeptides for Controlling Endoparasites and a Process for Their Preparation | BAYER HEALTHCARE AG (DE) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080026990-A1 | 18-Membered Nitrobenzyl- and Aminobenzyl-Substituted Cyclohexadepsipeptides for Controlling Endoparasites and a Process for Their Preparation | CBR3, C3AR1, EDNRB | LTA4H 926/4885HPGD 1715/4885MME 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.